Ordinary Index Rebalancing in the Solactive China Biotech Indices | May 2019

In the ordinary rebalance the following composition will be implemented:

LIVZON PHARMACEUTICAL GROU-A
HUALAN BIOLOGICAL ENGINEER-A
SHANGHAI RAAS BLOOD PRODUC-A
SINO BIOPHARMACEUTICAL LTD ORD
3SBIO INC
GENSCRIPT BIOTECH CORP
INNOVENT BIOLOGICS INC
LUYE PHARMA GROUP LTD
WUXI BIOLOGICS CAYMAN INC
ANHUI ANKE BIOTECHNOLOGY G-A
WALVAX BIOTECHNOLOGY CO-A
BETTA PHARMACEUTICALS CO L-A
SHENZHEN KANGTAI BIOLOGICA-A
BGI GENOMICS CO LTD-A
BEIJING TIANTAN BIOLOGICAL-A
JIANGSU HENGRUI MEDICINE CO LTD CLASS A
WUXI APPTEC CO LTD-A
BEIGENE LTD-ADR
CHINA BIOLOGIC PRODUCTS HOLD
HUTCHISON CHINA MEDITECH-ADR